Another important IVD market in France is that the country's private medical analysis laboratories merge into larger units. Usually, several private laboratories join together as a Sociétésd' Exercise Liberal (liberal exercise company) known in France as an SEL. Within an SEL, each laboratory specializes in a specific type of analysis. Besides, the consolidating and regrouping of laboratories also lead to a rapidly shrinking number of biologists and laboratories, especially private laboratories, in the past few years. However, these changes are complex at first but could make the market more efficient in the long run. The France IVD Market Size was valued at US$ 1.9 Billion in 2020.
The diagnostic tests in the country are assigned as a reimbursement percentage depending on the type of test, so the biologists in a public or a private laboratory can choose whatever brands of reagent they wish to use for a given diagnostic. However, regardless of their choices, they have reimbursed the percentage of cost predetermined for that kind of test. In general, the rates of reimbursement for France's public health insurance are as follows:
- Screenings for HIV or Hepatitis C are entirely free for all patients.
- Other laboratory analyses reimbursed at 60-70 percent for most patients (private insurance will generally reimburse the remaining 30-40 percent)
In the France IVD market segments, significant growth has happened in the Infectious Immunology segment in the year 2020. Other segments, Hematology, Immunochemistry, Microbiology, Bio-chemistry, and Genetic Testing have a slight decline for one year. But all these segments are expected to keep on growing in the long run. Clinical chemistry plays a crucial role in the France IVD market. The market for reagents has continued to grow in the past few years. The French IVD Industry is expected to increase marginally at a CAGR of 1.68% during 2020-2026.
France being a developed region with a well-structured healthcare system has many players in the in-vitro diagnostics market. Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific and Sysmex Corporation are prime companies in the France In-Vitro Diagnostics (IVD) Market.
COVID-19 Impact on IVD Market of France:
In the France IVD market, Infectious disease tests, particularly for respiratory and hospital-acquired infections, are anticipated to have strong growth.
Medical tests deemed non-essential, say routine health checks, bone health, hormone, will suffer the most due to postponement. More on this essential IVD tests for life-threatening conditions like cardiac, transplant, cancer, obstetrics, blood screening will be less affected.
A general drop of inpatient visits to hospitals and clinics has occurred as a result of lockdown measures.
Large investments in new diagnostic instruments not related to infectious disease testing will slow down as hospitals and labs prepare for the predicted economic downturn.
This report titled “France In-Vitro Diagnostics (IVD) Market By Segments (Immunochemistry, Hematology, Infectious Immunology, Microbiology, Bio-chemistry, Genetic Testing), Types (Laboratory Reagents, Instruments), Companies (Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific, Sysmex Corporation)” provides a complete analysis of France In-Vitro Diagnostics (IVD) Industry.
Types - France In-Vitro Diagnostics (IVD) Market have been covered from 2 viewpoints:
1. Laboratory Reagents
2. Instruments
Segments - France In-Vitro Diagnostics (IVD) Market have been covered from 6 viewpoints:
1. Immunochemistry
2. Hematology
3. Infectious Immunology
4. Microbiology
5. Bio-chemistry
6. Genetic Testing
Reimbursement Policy
1. Public
2. Private & Insurance
Companies have been covered from 3 viewpoints
- Overview
- Initiatives & Recent Developments
- Sales
Company Analysis
1. Roche Diagnostics
2. Abbott Diagnostics
3. Siemens Healthineers
4. Danaher Corporation
5. Thermo Fisher Scientific
6. Sysmex Corporation
Table of Contents
Companies Mentioned
- Roche Diagnostics
- Abbott Diagnostics
- Siemens Healthineers
- Danaher Corporation
- Thermo Fisher Scientific
- Sysmex Corporation
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| Published | June 2021 |
| Forecast Period | 2020 - 2026 |
| Estimated Market Value ( USD | $ 1.9 Billion |
| Forecasted Market Value ( USD | $ 2.1 Billion |
| Compound Annual Growth Rate | 1.6% |
| Regions Covered | France |
| No. of Companies Mentioned | 6 |
![Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]), Cancer Type (Breast, Lung, Colon, Prostate), and End User (Hospital, Imaging Center, Pharmaceutical) - Forecast to 2031 - Product Image](http://www.researchandmarkets.com/product_images/12622/12622545_60px_jpg/europe_cancer_diagnostics_market.jpg)
